Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA.
Walsh EM, et al. Among authors: lamparella n.
Breast Cancer Res Treat. 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20.
Breast Cancer Res Treat. 2022.
PMID: 35986801
Free PMC article.